

## Supplementary Material

### The Time-Course of Cancer Recurrence with Physical Activity in Stage III Colon Cancer


Justin C. Brown, Ph.D.<sup>1,2,3</sup>; Chao Ma, M.S.<sup>4</sup>; Qian Shi, Ph.D.<sup>5</sup>; Donna Niedzwiecki, Ph.D.<sup>6</sup>; Tyler Zemla, M.S.<sup>5</sup>; Felix Couture, M.D.<sup>7</sup>; Philip Kuebler, M.D.<sup>8</sup>; Pankaj Kumar, M.D.<sup>9</sup>; Judith O. Hopkins, M.D.<sup>10</sup>; Benjamin Tan, M.D.<sup>11</sup>; Smitha Krishnamurthi, M.D.<sup>12</sup>; Eileen M. O'Reilly, M.D.<sup>13</sup>; Anthony F. Shields, M.D.<sup>14</sup>; Jeffrey A. Meyerhardt, M.D., M.P.H.<sup>4</sup>

<sup>1</sup>Pennington Biomedical Research Center Baton Rouge, LA, U.S.A.; <sup>2</sup>LSU Health Sciences Center, New Orleans School of Medicine, New Orleans, LA, U.S.A.; <sup>3</sup>Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, U.S.A.; <sup>4</sup>Dana-Farber/Partners CancerCare, Boston, MA, U.S.A.; <sup>5</sup>Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, U.S.A.; <sup>6</sup>Duke Cancer Institute-Biostatistics, Duke University, Durham, NC, U.S.A.; <sup>7</sup>Hôtel-Dieu de Québec, Québec, Canada; <sup>8</sup>Columbus NCI Community Oncology Research Program, Columbus, OH, U.S.A.; <sup>9</sup>Heartland Cancer Research NCORP, Illinois CancerCare PC, Peoria, IL, U.S.A.; <sup>10</sup>Southeast Clinical Oncology Research Consortium, Novant Health Kernersville Medical Center, Kernersville, NC, U.S.A.; <sup>11</sup>Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, U.S.A.; <sup>12</sup>Cleveland Clinic, Cleveland, OH, U.S.A.; <sup>13</sup>Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY, U.S.A.; <sup>14</sup>Karmanos Cancer Institute, Wayne State University, MI, U.S.A.

#### Corresponding Author:

Justin C. Brown, Ph.D.  
6400 Perkins Road  
Baton Rouge, LA 70808  
Phone: 225-763-2715  
Email: [Justin.Brown@pbrc.edu](mailto:Justin.Brown@pbrc.edu)

**Supplementary Figure 1.** Graphical sketch of confounder-adjusted hazard rates by physical activity category. In Panel A, the hazard rate of cancer recurrence in the physically active group (blue line) is never higher than in the physically inactive group (red line), and the lines remain separated during follow-up. Panel A is consistent with the hypothesis that physical activity prevents cancer recurrence. In Panel B, the hazard rate of recurrence is initially higher in the physically inactive group, but with advancing time, the hazard rate of the physically active group becomes higher, and the lines eventually converge during follow-up. Panel B is consistent with the hypothesis that physical activity delays cancer recurrence.



**Supplementary Table 1.** Association of physical activity with time to cancer recurrence

Physical Activity Volume (MET-h/wk)	1-y Recurrence Rate (95% CI) <sup>a,b</sup>	2-y Recurrence Rate (95% CI) <sup>a,b</sup>	3-y Recurrence Rate (95% CI) <sup>a,b</sup>	5-y Recurrence Rate (95% CI) <sup>a,b</sup>	Hazard Ratio (95% CI) <sup>a</sup>
<9.0	6.7 (4.8, 9.5)	13.1 (9.5, 18.3)	19.3 (14.0, 26.8)	31.5 (22.8, 44.2)	1.00—Reference
≥9.0	4.4 (3.1, 6.0)	8.5 (6.1, 11.5)	12.5 (9.1, 16.9)	20.4 (14.8, 27.6)	0.65 (0.49, 0.82)
<b>Absolute Risk Difference<sup>c</sup></b>	2.3 (0.1, 4.5)	4.6 (1.7, 7.5)	6.8 (3.3, 10.2)	11.1 (7.0, 15.2)	—
<b>p<sup>d</sup></b>	0.040	0.002	<0.001	<0.001	<0.001
<b>NNT<sup>e</sup></b>	44 (22, 1000)	22 (13, 59)	15 (10, 30)	9 (7, 14)	—

Abbreviations: MET-h/wk, metabolic equivalent total physical activity energy expenditure; y, year; NNT, number needed to treat

<sup>a</sup>Adjusted for age, sex, race, extent of invasion through the bowel wall, nodal stage, tumor location, ECOG performance status, low dose aspirin use, smoking history, body mass index (time-varying), western dietary pattern (time-varying), prudent dietary pattern (time-varying), chemotherapy randomization, and pharmacotherapy randomization. Continuous covariates were modeled linearly, and categorical covariates were modeled using the categories presented in Table 1.

<sup>b</sup>Covariates for predicting recurrence rates were set to the mean of the study population for continuous variables and most common categories for categorical variables.

<sup>c</sup>95% confidence intervals were calculated via the bootstrap method with 1,0000 replicates.

<sup>d</sup>P values are two-sided.

<sup>e</sup>The number needed to treat (NNT) was calculated as 1/Absolute Risk Difference. The NNT quantifies the number of patients who would need to be become physically active to prevent one cancer recurrence.

**Supplementary Table 2.** Model performance between the flexible parametric model with Weibull distribution and Cox proportional hazards model

<b>Endpoint</b>	<b>Akaike Information Criterion (AIC)</b>		<b>Bayesian Information Criterion (BIC)</b>	
	<b>Weibull</b>	<b>Cox</b>	<b>Weibull</b>	<b>Cox</b>
Disease-Free Survival	3177	6384	3303	6462
Time to Cancer Recurrence	2843	5551	2968	5626
Overall Survival	2308	3932	2434	4001